Navigation Links
Watson Launches Generic LoSEASONIQUE(R)
Date:12/7/2011

PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s  LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy.  Terms of the settlement were not disclosed.

As a "first applicant" to submit a substantially complete ANDA, Watson is eligible for 180 days of shared generic market exclusivity.  For the most recent twelve months ending September 30, 2011, LoSEASONIQUE® had sales of approximately $28 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LoSEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS: Investors: 

Patty Eisenhaur 

(862) 261-8141

 Media: 

Charlie Mayr 

(862) 261-8030   


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic LIPITOR®
2. Watson to Present at the 2011 Piper Jaffray Health Care Conference
3. Watson Wins Kentucky Drug Pricing Litigation
4. Watson Confirms Exelon(R) Patent Challenge
5. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
6. Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
7. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
8. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
9. Watson Confirms Daytrana(R) Patent Challenge
10. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
11. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 bioLytical Laboratories, un líder mundial en test rápidos ... HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la ...
(Date:12/2/2016)... held the largest share in the ECG Cables And ECG ... for remote monitoring ECG devices. On the other hand, the ... witness the highest growth rate during the forecast period. ... and Company (U.S.), Medtronic plc ( Ireland ), ... Mindray Medical International Limited ( China ), held ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... 2016 , ... Penrose Senior Care Auditors® was announced as ... at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet held ... Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment and ...
(Date:12/4/2016)... ... ... Are You Concerned About Mold In Your Home or Workplace? Madison ... in VA, MD and DC, recently completed its application for the new District of ... the district of Columbia is a good thing stated John Taylor, Owner of Madison ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... ... For over twenty-four years, Doctors on Liens has published a directory of the ... medical care. When the company started in 1997, the directory was a single page ... the now ten-page directory features a vast array of medical specialists stretching from ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
Breaking Medicine News(10 mins):